Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism

6 Feb 2013

Abstract excerpt

BACKGROUND: Resistance to chemotherapy represents a significant obstacle in prostate cancer therapeutics. Novel mechanistic understandings in cancer cell chemotherapeutic sensitivity and resistance can optimize treatment and improve patient outcome. Molecular alterations in the metabolic pathways are associated with cancer development; however, the role of these alterations in chemotherapy efficacy is largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Mitochondrial Function and Pathology
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23389923
DOI: 10.1002/pros.22650

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolismPMID 23389923Read ↗

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancerSemantic proximity Read ↗

Clofazimine treatment modulates key non-coding RNAs associated with tumor progression and drug resistance in lethal Prostate CancerSemantic proximity Read ↗

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancerSemantic proximity Read ↗

Changes in PKM2 associate with prostate cancer progression.Semantic proximity Read ↗

LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate CancerSemantic proximity Read ↗

A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.Semantic proximity Read ↗

Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate CancerSemantic proximity Read ↗

Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancerSemantic proximity Read ↗

Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.Semantic proximity Read ↗

Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancerSemantic proximity Read ↗

Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate CancerSemantic proximity Read ↗

OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.